You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

MICRO-K 10 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Micro-k 10 patents expire, and when can generic versions of Micro-k 10 launch?

Micro-k 10 is a drug marketed by Nesher Pharms and is included in one NDA.

The generic ingredient in MICRO-K 10 is potassium chloride. There are two hundred and forty drug master file entries for this compound. Eighty-eight suppliers are listed for this compound. Additional details are available on the potassium chloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Micro-k 10

A generic version of MICRO-K 10 was approved as potassium chloride by ACTAVIS LABS FL INC on April 10th, 2002.

  Try a Trial

US Patents and Regulatory Information for MICRO-K 10

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nesher Pharms MICRO-K 10 potassium chloride CAPSULE, EXTENDED RELEASE;ORAL 018238-002 May 14, 1984 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for MICRO-K 10

See the table below for patents covering MICRO-K 10 around the world.

Country Patent Number Title Estimated Expiration
Belgium 886973 ⤷  Try a Trial
Australia 6589880 ⤷  Try a Trial
France 2484254 ⤷  Try a Trial
United Kingdom 2077587 CONTROLLED RELEASE POTASSIUM DOSAGE FORM ⤷  Try a Trial
Philippines 15605 CONTROLLED RELEASE POTASSIUM DOSAGE FORM ⤷  Try a Trial
Netherlands 192430 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for MICRO-K 10

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1441735 08C0026 France ⤷  Try a Trial PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102
1718641 SPC/GB12/028 United Kingdom ⤷  Try a Trial PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
0733366 SPC/GB98/031 United Kingdom ⤷  Try a Trial PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
1718641 2012/008 Ireland ⤷  Try a Trial PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
1441735 2008/010 Ireland ⤷  Try a Trial PRODUCT NAME: RALTEGRAVIR OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; NAT AUTHORISTION NO/DATE: EU/1/07/436/001-002 20071220;
1441735 SPC/GB08/020 United Kingdom ⤷  Try a Trial PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.